Currently, the main drugs to improve insulin resistance were thiazolidinediones (TZD) (pioglitazone) and PPAR full agonists (selegiline sodium) and others, but they have been associated with side effects including sodium retention, edema, congestive heart failure, and damage liver and kidney functions (45, 46). This evidence concerns the gene PPARA and Insulin resistance.